Zydus Lifesciences Q4 Net Profit ₹12.7B, Recommends Dividend

• Board approved audited FY26 results with unmodified audit opinion from Deloitte Haskins & Sells LLP.
• Recommended a final dividend of ₹1 per share (100%) subject to shareholder approval at the AGM on August 11, 2026.
• Consolidated Q4 revenue grew to ₹77.2B with net profit of ₹12.7B; full-year profit reached ₹50.4B.
• Disclosed one-time impacts from labour code changes (₹849M) and a legal settlement (₹3.98B) with Astellas Pharma.